Neuroendocrine neoplasm

This phase 2 pilot study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with liver-directed treatments (like embolization or radiation) or peptide receptor radionuclide therapy (PRRT) can shrink tumors in people with well-differentiated neuroendocrine tum…

This phase 2 trial is testing an investigational drug called nab-sirolimus in people with advanced neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas. Participants must have had up to two prior lines of therapy (excluding somatostatin analogs) and must …

This phase II trial tests whether combining the immunotherapy drug nivolumab with the chemotherapy drug temozolomide can shrink tumors in people with small-cell lung cancer that has returned or not responded to treatment, or advanced neuroendocrine tumors. About 55 participants w…

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…

This study followed 164 adults with advanced, progressive neuroendocrine tumors of the gut or pancreas who were treated with Lutathera (a radioactive drug) in normal hospital settings. Researchers measured how long patients lived without their cancer getting worse and how many tu…

This study tested whether adding the drug axitinib to standard sandostatin LAR therapy could slow tumor growth in 256 people with advanced neuroendocrine tumors (G1-G2) that started outside the pancreas. Participants received either the combination or sandostatin plus a placebo. …

This early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal wa…

This early-phase trial tested the safety and best dose of the immunotherapy drug pembrolizumab when combined with chemotherapy and radiation for people with small cell lung cancer. The goal was to see if adding pembrolizumab helps the immune system fight the cancer more effective…

This early-phase trial tested a vaccine called SurVaxM in 19 people with metastatic neuroendocrine tumors. The vaccine is designed to teach the immune system to recognize and attack tumor cells that produce a protein called survivin. The main goal was to see if the vaccine is saf…

This phase II trial tested a treatment called TheraSphere selective internal radiation therapy (SIRT) in 24 patients with neuroendocrine tumors that had spread to the liver and could not be surgically removed. The treatment involves injecting tiny radioactive beads into the liver…

This phase 2 trial tested a combination of two drugs—pembrolizumab (Keytruda) and lenvatinib (Lenvima)—in 20 people with advanced neuroendocrine tumors that had worsened despite prior treatments. The goal was to see if the combination could shrink tumors or slow disease progressi…

This study tested a daily pill called surufatinib in 36 Japanese patients with neuroendocrine tumors that had stopped responding to other treatments. The goal was to see if the drug is safe and whether it can shrink tumors. The trial combined an early safety phase with a later ph…

This study tests whether measuring gene transcripts in the blood can help diagnose neuroendocrine tumors and assess how completely surgery removed them. Researchers will track blood levels after surgery and compare them with imaging to see if a rise in these markers signals tumor…

This early-phase study tested a new way to make a radioactive tracer called 68Ga-DOTATOC for PET-CT scans in 20 adults with suspected or known neuroendocrine tumors. The goal was to see if this new method could find tumors more accurately than the current standard scan (OctreoSca…

This early study tested a new radioactive tracer called [18F]3F-PHPG to see if it can help locate neuroendocrine tumors during PET scans. 32 adults with these tumors received the tracer and had two scans. The goal was to check image quality and how the tracer spreads in the body,…

This study tested a new imaging method called [68Ga]Ga-DOTA-TATE PET/CT to see how well it finds neuroendocrine tumors compared to standard scans. It included 71 adults in Japan, both with and without the disease. The goal was to prove the new scan works well for diagnosis in Jap…

This Phase 2 trial tested paltusotine, an oral drug, in 36 adults with carcinoid syndrome. The study looked at safety and how the body processes the drug at different doses. Participants were randomly assigned to 40 mg or 80 mg daily, with dose adjustments allowed. The goal is to…

This study looks back at the medical records of 88 adults with neuroendocrine tumors that have spread or cannot be removed. Researchers will examine how different patient characteristics and treatments relate to overall survival and other outcomes. The goal is to identify factors…

This study tested whether a new type of camera (VERITON-CT) can accurately measure radiation doses in patients receiving Lutathera, a treatment for certain cancers. Fifteen adults were scanned with both the new camera and a standard camera at different times after treatment. The …

This completed Phase 1 study tested whether a PET scan using 64Cu-DOTATATE (Detectnet) can help doctors plan safer doses of Lutathera therapy for people with neuroendocrine tumors. Four participants received both standard Lutathera treatment and extra PET/CT and SPECT/CT scans to…

This study looked at 117 people with gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) who received a type of radiation therapy called PRRT in German clinics. Researchers collected information on patient characteristics, treatment timing, and how PRRT was given in everyday…

This study analyzed data from 168 patients with a rare type of digestive neuroendocrine tumor (well-differentiated grade 3). Researchers compared survival and response rates in patients who received platinum-based chemotherapy versus those who received non-platinum chemotherapy. …

This study looked at 116 people with advanced neuroendocrine tumors to see if a marker called MGMT can predict which chemotherapy works best. Researchers compared two chemo types—alkylating agents and oxaliplatin—based on MGMT status. The goal is to personalize treatment and impr…

This study tested the EchoTip AcuCore, a needle used during endoscopic ultrasound to collect tissue samples from the pancreas, liver, and other organs. 183 adults with conditions like cancer or chronic pancreatitis took part. The main goal was to see if the needle could get a goo…

This study follows 20 people with neuroendocrine tumors who previously received a radioactive drug called 177Lu-satoreotide tetraxetan. Researchers check for long-term side effects, including new cancers, every 3 months for up to 5 years. The goal is to understand the drug's safe…